BLN 326
Alternative Names: BLN-326; BMS-986326Latest Information Update: 28 May 2026
At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Interleukin 2 receptor agonists; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis; Autoimmune disorders
- No development reported Immunological disorders
Most Recent Events
- 28 May 2026 No recent reports of development identified for phase-I development in Immunological-disorders(In volunteers) in Germany (IV)
- 28 May 2026 No recent reports of development identified for phase-I development in Immunological-disorders(In volunteers) in Germany (SC)
- 14 Apr 2026 Bristol-Myers Squibb completes phase-I clinical trials in Autoimmune disorders in Romania, Spain, Poland, Netherlands, Bulgaria, Germany, Argentina, USA (SC/IV) (NCT06013995)